請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19631
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賴美淑 | |
dc.contributor.author | Meng-Sui Lee | en |
dc.contributor.author | 李孟穗 | zh_TW |
dc.date.accessioned | 2021-06-08T02:09:48Z | - |
dc.date.copyright | 2016-02-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-01-28 | |
dc.identifier.citation | 1. Raychaudhuri SP , Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16-17.
2. Grozdev I, Korman N , Tsankov N. Psoriasis as a systemic disease. Clin Dermatol 2014;32:343-350. 3. Abuabara K, Azfar RS, Shin DB et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010;163:586-592. 4. Salahadeen E, Torp-Pedersen C, Gislason G et al. Nationwide population-based study of cause-specific death rates in patients with psoriasis. J Eur Acad Dermatol Venereol 2014. 5. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-1499. 6. Mehta NN, Azfar RS, Shin DB et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-1006. 7. Ahlehoff O, Gislason GH, Charlot M et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147-157. 8. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741. 9. Kaye JA, Li L , Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159:895-902. 10. Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298:321-328. 11. Brauchli YB, Jick SS , Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008;159:1331-1337. 12. Gelfand JM, Dommasch ED, Shin DB et al. The Risk of Stroke in Patients with Psoriasis. J Invest Dermatol 2009;129:2411-2418. 13. Pehlevan S, Yetkin DO, Bahadir C et al. Increased prevalence of metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2014;12:43-48. 14. Brauchli YB, Jick SS, Miret M et al. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009;160:1048-1056. 15. Brenaut E, Horreau C, Pouplard C et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2013;27 Suppl 3:30-35. 16. Armstrong AW, Harskamp CT, Dhillon JS et al. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol 2014;170:304-314. 17. Torres T, Chiricozzi A, Chimenti S et al. Genetic markers for cardiovascular disease in psoriasis: the missing piece. Mol Diagn Ther 2014;18:93-95. 18. Ridker PM, Wilson PW , Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004;109:2818-2825. 19. van Leuven SI, Franssen R, Kastelein JJ et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008;47:3-7. 20. Freitas DS, Camargo CZ, Mariz HA et al. Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques. Rheumatol Int 2012;32:703-709. 21. Solomon DH, Massarotti E, Garg R et al. Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis. JAMA 2011;305:2525-2531. 22. Grossman RM, Delaney RJ, Brinton EA et al. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine. J Am Acad Dermatol 1991;25:648-651. 23. Robert N, Wong GW , Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010:CD007893. 24. Buckingham BA , Sandborg CI. A Randomized Trial of Methotrexate in Newly Diagnosed Patients with Type 1 Diabetes Mellitus. Clin Immunol 2000;96:86-90. 25. Matheson DS, Green B , Hoar DI. The influence of methotrexate and thymidine on the human natural killer cell function in vitro. J Immunol 1983;131:1619-1621. 26. Malerba M, Gisondi P, Radaeli A et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006;155:1165-1169. 27. Tsai T-F, Wang T-S, Hung S-T et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011;63:40-46. 28. Nevitt GJ , Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. British Journal of Dermatology 1996;135:533-537. 29. Love TJ, Qureshi AA, Karlson EW et al. Prevalence of the metabolic syndrome in psoriasis: Results from the national health and nutrition examination survey, 2003-2006. Arch Dermatol 2011;147:419-424. 30. Li W, Han J, Hu FB et al. Psoriasis and Risk of Type 2 Diabetes among Women and Men in the United States: A Population-Based Cohort Study. J Invest Dermatol 2012;132:291-298. 31. Armstrong AW, Harskamp CT , Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013;149:84-91. 32. Mirhafez SR, Mohebati M, Feiz Disfani M et al. An imbalance in serum concentrations of inflammatory and anti-inflammatory cytokines in hypertension. J Am Soc Hypertens 2014;8:614-623. 33. Fernandez-Real JM , Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Reviews 2003;24:278-301. 34. Nandeesha H, Bobby Z, Selvaraj N et al. Pre-hypertension: Is it an inflammatory state? Clin Chim Acta 2015;451:338-342. 35. Shoelson SE, Lee J , Goldfine AB. Inflammation and insulin resistance. Journal of Clinical Investigation 2006;116:1793-1801. 36. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952. 37. Armstrong AW, Harskamp CT , Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013;31:433-442. 38. Qureshi AA, Choi HK, Setty AR et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009;145:379-382. 39. Qureshi AA, Choi HK, Setty AR et al. Psoriasis and the Risk of Diabetes and Hypertension: A Prospective Study of US Female Nurses. Arch Dermatol 2009;145:379-382. 40. Miller IM, Ellervik C, Yazdanyar S et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol 2013;69:1014-1024. 41. Lin HW, Wang KH, Lin HC et al. Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan. J Am Acad Dermatol 2011;64:495-501. 42. Ahlehoff O, Gislason GH, Jorgensen CH et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012;33:2054-2064. 43. Gelfand JM, Dommasch ED, Shin DB et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009;129:2411-2418. 44. Armstrong EJ, Harskamp CT , Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2013;2:e000062. 45. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-230. 46. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-485. 47. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-850. 48. Chang YT, Chen TJ, Liu PC et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm Venereol 2009;89:262-266. 49. Gottlieb AB, Grossman RM, Khandke L et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992;98:302-309. 50. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for Plaque-Type Psoriasis. N Engl J Med 1991;324:277-284. 51. Ho VC, Griffiths CE, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001;44:643-651. 52. Gisondi P, Cazzaniga S, Chimenti S et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol 2013;27:e30-41. 53. Lowe NJ, Wieder JM, Rosenbach A et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1996;35:710-719. 54. Hoorn EJ, Walsh SB, McCormick JA et al. Pathogenesis of calcineurin inhibitor-induced hypertension. J Nephrol 2012;25:269-275. 55. Dufer M, Krippeit-Drews P, Lembert N et al. Diabetogenic effect of cyclosporin A is mediated by interference with mitochondrial function of pancreatic B-cells. Mol Pharmacol 2001;60:873-879. 56. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997;17:277-289. 57. Conn HO , Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-632. 58. Grossman E , Messerli FH. Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 2008;10:556-566. 59. Kalb RE, Strober B, Weinstein G et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-837. 60. Cronstein BN. Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis. Pharmacological Reviews 2005;57:163-172. 61. Micha R, Imamura F, Wyler von Ballmoos M et al. Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease. The American Journal of Cardiology 2011;108:1362-1370. 62. Almalag HM, Mangoni AA , Crilly MA. Methotrexate and Risk of Cardiovascular Disease. The American Journal of Cardiology 2012;109:1383-1384. 63. Zhang Z, Zhao P, Li A et al. Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. Mediators Inflamm 2009;2009:389720. 64. van Ede AE, Laan RF, Blom HJ et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:658-665. 65. De Bree A, Verschuren WM, Kromhout D et al. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002;54:599-618. 66. Morgan SL, Baggott JE, Lee JY et al. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998;25:441-446. 67. Whittle SL , Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004;43:267-271. 68. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-1177. 69. Prodanovich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-267. 70. Solomon DH, Avorn J, Katz JN et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-3798. 71. Lan CC, Ko YC, Yu HS et al. Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study. Acta Derm Venereol 2012;92:349-352. 72. Ahlehoff O, Skov L, Gislason G et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 2015;29:1128-1134. 73. Chen YJ, Chang YT, Shen JL et al. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. Arthritis Rheum 2012;64:1879-1887. 74. Cox E, Martin BC, Van Staa T et al. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report--Part II. Value Health 2009;12:1053-1061. 75. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19:858-868. 76. Lubin JH. Extensions of analytic methods for nested and population-based incident case-control studies. J Chronic Dis 1986;39:379-388. 77. Rosenbaum PR , Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55. 78. Mack CD, Glynn RJ, Brookhart MA et al. Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf 2013;22:810-818. 79. Hernan MA , Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 2012;9:48-55. 80. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006;15:291-303. 81. Yoshida K, Solomon DH , Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 2015;11:437-441. 82. Universal Health Coverage in Taiwan. Taipei: Bureau of National Health Insurance, Department of Health, Executive Yuan; 2011. 83. Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-858. 84. Stricker BH , Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. Eur J Epidemiol 2010;25:245-251. 85. Margolis D, Bilker W, Hennessy S et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-783. 86. Gelfand JM, Shin DB, Neimann AL et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-2201. 87. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004;61:e59. 88. Delgado-Rodriguez M , Llorca J. Bias. J Epidemiol Community Health 2004;58:635-641. 89. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care 2005;43:1130-1139. 90. Hernan MA , Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006;60:578-586. 91. Cole SR , Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 2004;75:45-49. 92. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424. 93. Jacobs DR, Jr., Adachi H, Mulder I et al. Cigarette smoking and mortality risk: twenty-five-year follow-up of the Seven Countries Study. Arch Intern Med 1999;159:733-740. 94. D’Agostino RB, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: The framingham heart study. Circulation 2008;117:743-753. 95. Lin TY, See LC, Shen YM et al. Quality of life in patients with psoriasis in northern Taiwan. Chang Gung Med J 2011;34:186-196. 96. Boehncke WH, Boehncke S, Tobin AM et al. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-307. 97. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867. 98. Campalani E, Allen MH, Fairhurst D et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006;154:345-352. 99. Wolf N, Quaranta M, Prescott NJ et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 2008;45:114-116. 100. Lu Y, Chen H, Nikamo P et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol 2013;133:836-839. 101. Su YS, Yu HS, Li WC et al. Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy. J Eur Acad Dermatol Venereol 2013;27:876-883. 102. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342. 103. Avina-Zubieta JA, Abrahamowicz M, De Vera MA et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013;52:68-75. 104. Schacke H, Docke WD , Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43. 105. Piot C, Croisille P, Staat P et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481. 106. Ferrandiz C, Pujol RM, Garcia-Patos V et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002;46:867-873. 107. Henseler T , Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-456. 108. Langley RG, Krueger GG , Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64 Suppl 2:ii18-23. 109. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695. 110. Song JW , Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg 2010;126:2234-2242. 111. Essebag V, Genest Jr J, Suissa S et al. The nested case-control study in cardiology. Am Heart J 2003;146:581-590. 112. Glynn RJ, Knight EL, Levin R et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001;12:682-689. 113. Lee WC. Bounding the bias of unmeasured factors with confounding and effect-modifying potentials. Stat Med 2011;30:1007-1017. 114. Rothman KJ, Greenland S , Lash TL. Modern Epidemiology: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008. 115. Velentgas PT, Nancy A. Dreyer, Parivash Nourjah, Scott R. Smith, and Marion Torchia. Developing a protocol for observational comparative effectiveness research : a user's guide: Rockville, MD : U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality, 2013.; 2013. 116. Berger ML, Mamdani M, Atkins D et al. Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I. Value in Health;12:1044-1052. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19631 | - |
dc.description.abstract | 乾癬是一種慢性發炎疾病,有越來越多的證據顯示慢性發炎反應在腹部肥胖、代謝症候群、糖尿病、高血壓及心血管疾病扮演重要角色。目前的研究顯示乾癬病人有較高糖尿病及高血壓的發生率及盛行率,尤其是嚴重型乾癬的病人,但之前的研究並未考量乾癬常用藥物及共病症對乾癬病人發生糖尿病及高血壓的影響。系統性的乾癬治療藥物: 環孢靈素、非類固醇抗發炎藥物及類固醇可能會誘發高血壓; 環孢靈素、類固醇及methotrexate可能會誘發糖尿病。然而methotrexate抗發炎的特性被認為可能可以減少乾癬病人發生心血管疾病的風險,但因為methotrexate會造成hyperhomocysteinemia而引起缺血性心血管疾病,心血管疾病造成乾癬病人重大的疾病負擔及也是乾癬病人主要的死亡原因。因此系統性的乾癬治療藥物對於發生心血管疾病危險因子及結果的影響是很重要的議題。
本研究的目的為利用臺灣健保資料庫估算乾癬病人的糖尿病及高血壓的發生率及發生風險,及系統性的乾癬治療藥物對於病人發生糖尿病、高血壓及心血管疾病的影響。 考量乾癬病人的常見藥物及共病症的影響,乾癬病人有較高發生糖尿病及高血壓的風險。乾癬病人現在使用環孢靈素、非類固醇抗發炎藥物及類固醇相對於未使用有較高的風險發生高血壓; 現在使用類固醇及methotrexate相對於未使用有較高的風險發生糖尿病;使用methotrexate相對於使用retinoid發生心血管疾病的風險較低。 總結來看,乾癬病人有較高的風險發生糖尿病及高血壓的風險,雖然系統性的乾癬治療藥物有抗發炎的效果,但是各個藥物對心血管疾病的危險因子及結果影響不同,因此臨床醫師使用這些藥物時需審慎評估早期發現心血管疾病危險因子之發生。 | zh_TW |
dc.description.abstract | Psoriasis is a common chronic inflammatory skin disease. There is a growing body of evidence to suggest that chronic silent inflammation is a key feature in abdominal obesity, metabolic syndrome, diabetes mellitus (DM), hypertension, and cardiovascular disease (CVD). Psoriasis is associated with an increased prevalence and incidence of DM and hypertension. The association of psoriasis with DM or hypertension may be strongest among patients with severe psoriasis. However, most of these studies did not completely adjust for other covariates that may predispose to DM and hypertension. Systemic anti-inflammatory treatments for psoriasis, such as cyclosporine, non-steroidal anti-inflammatory drugs, and systemic corticosteroids, may induce hypertension. Cyclosporine, systemic corticosteroids, and methotrexate can potentially increase DM progression. The anti-inflammatory properties of methotrexate have been hypothesized to be beneficial in reducing CVD risk in patients with psoriasis and/or psoriatic arthritis (PsA). However, methotrexate therapy may promote hyperhomocysteinemia and thereby increase the risk of ischemic CVD. The high prevalence and serious health impacts of cardiovascular morbidity and mortality has been recognized in patients with psoriasis and/or PsA; therefore, the risk or benefit of anti-psoriatic systemic therapy on cardiovascular morbidity and mortality is an important issue.
This study sought to estimate the incidence and risk of newly diagnosed DM, and hypertension, and the risk or effectiveness of anti-psoriatic systemic therapy on newly diagnosed DM, hypertension, and cardiovascular outcomes in patients with psoriasis and/or PsA using the databases of the National Health Insurance and National Death Registry to create a nationwide cohort with a large population base. After adjusting for comorbidities and concomitant medications, psoriasis was found to be independently associated with an increased risk of DM and hypertension. After adjustment for potential confounders, patients with current use of cyclosporine, nonsteroidal anti-inflammatory drugs, or systemic glucocorticoids showed an increased risk of hypertension as compared to those not exposed to these drugs. The current use of methotrexate, and glucocorticoids were associated with newly diagnosed DM. Furthermore, we found that patients with psoriasis who were receiving methotrexate therapy were less likely to develop cardiovascular events than those receiving retinoid treatments. In summary, the patients with psoriasis and/or PsA had a higher risk of DM and hypertension. Although systemic therapy has been focused on the anti-inflammatory pathogenesis of psoriasis, the effects on CVD risk factors and outcomes depend on the drug itself, and the treatment strategy in patients with psoriasis may have an effect on cardiovascular outcomes. Therefore, CVD risk should be evaluated before starting treatment with any drug. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:09:48Z (GMT). No. of bitstreams: 1 ntu-105-D01849016-1.pdf: 1208080 bytes, checksum: 2e271178332df610c5fb29f72163c010 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 摘要 I
ABSTRACT II CONTENTS V CONTENTS OF FIGURES VIII CONTENTS OF TABLES XI CONTENTS OF SUPPLEMENTARY FIGURE XI CONTENTS OF SUPPLEMENTARY TABLES XI CHAPTER 1 Introduction 1 CHAPTER 2 Literature Review 4 2.1 Epidemiology of psoriasis 4 2.1.1 Epidemiology of cardiovascular risk factors in patients with psoriasis and/or psoriatic arthritis 5 2.1.2 Epidemiology of cardiovascular outcomes in patients with psoriasis and/or psoriatic arthritis 7 2.2 Current treatment in severe psoriasis and/or psoriatic arthritis 9 2.3 Studies on the effects of cyclosporine in patients with psoriasis and/or psoriatic arthritis 10 2.4 Studies on the effects of non-steroidal anti-inflammatory drugs and glucocorticoids in patients with psoriasis and psoriatic arthritis 11 2.5 Studies on the effect of methotrexate in patients with psoriasis and/or psoriatic arthritis 12 2.6 Biases in retrospective cohort and nested case | |
dc.language.iso | en | |
dc.title | 乾癬治療藥品對心血管疾病風險與結果評估 | zh_TW |
dc.title | Risk and Outcome Evaluation of Systemic Psoriasis Therapy on Cardiovascular Disease | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 李文宗,邵文逸,賴超倫,吳貞宜 | |
dc.subject.keyword | 糖尿病,高血壓,心血管疾病,系統性的乾癬治療藥物,慢性發炎反應, | zh_TW |
dc.subject.keyword | diabetes mellitus,hypertension,cardiovascular disease,systemic anti-psoriatic therapy,chronic inflammation, | en |
dc.relation.page | 107 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2016-01-28 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 1.18 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。